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Metastatic hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. However, the cell population responsible for its metastasis remains largely unknown. Here 
Introduction
Hepatocellular carcinoma (HCC), which accounts for 90% of primary liver cancers, is associated with a high mortality rate (16.1/10 5 ) worldwide and is the second leading cause of cancer-related deaths in China [1] . The post-surgical 5-year survival rate remains low, largely due to the high recurrence rate [2] . Intrahepatic and distant metastasis, mainly through hematogenous dissemination, is responsible for most cases of HCC relapse [3] . HCC vascular invasion, characterized by the formation of tumor thrombi in the portal or hepatic vein, is responsible for early recurrence and likely predicts poor prognosis [4, 5] . Therefore, it is urgent to understand the mechanisms of vascular invasion in liver cancers in order to develop novel treatments against HCC recurrence.
Hematogenous metastasis is an integrated and stepwise process in which tumor cells detach from the primary tumor into the stroma and invade blood vessels. This is followed by a secondary growth at a distant site [6] , during which only a small group of tumor cells manage to form distant metastatic lesions. However, the exact identity of these tumor cells is largely unknown. Recent evidence suggests the existence of tumor-initiating cells (TICs), a small population of tumor cells capable of sustaining tumor formation/growth [7, 8] . These tumors could develop from an extremely small number of cells when implanted into experimental animals; the cells divide to self-renew and generate progeny to create the tumor bulk. TICs are also important for metastasis in certain solid cancers, such as breast and pancreatic cancers [9, 10] . In liver cancers, CD133, a transmembrane hematopoietic stem cell antigen [11] , has been identified as a putative marker of TICs [12, 13] . Several immunohistochemical studies in HCC specimens have revealed controversial results regarding the association of CD133 expression with metastasis occurrence [14, 15] . However, direct evidence supporting a role of CD133 + cells in HCC metastasis is largely lacking. CD44, a molecule important for cell migration, is involved in the metastasis of multiple cancers, including liver cancer [16, 17] . We therefore hypothesized that CD133 + CD44 + cells might be the subgroup of tumor cells that is responsible for hematogenous metastasis in liver cancer.
In this study, we reported that CD133 
Results

CD133 expression was associated with vascular invasion in liver cancers
We first examined the expression of CD133 in human HCC specimens and normal liver tissues (NTs) by immunohistochemistry (IHC; Figure 1A ). As shown in Figure 1B and 1C, more CD133 + cells and cells with stronger CD133 staining were found in metastatic groups (M) compared to non-metastatic (NM) and NT groups. Furthermore, we did not find a significant difference in the number of CD133 + cells and their staining intensity between the primary tumors and the corresponding portal vein tumor thromboses (PVTTs), suggesting that primary tumors and the PVTT might have similar cells of origin. Collectively, these results suggest that an increased number of CD133 + tumor cells is associated with vascular invasion in HCC.
CD133 + tumor cells were superior in clonogenic growth but not in invasion
We next compared CD133 expression (Supplementary information, Table S1 ) and invasion ability in six HCC cell lines. Increased CD133 expression, as determined by transwell assay, was not associated with invasive abilities (Figure 2A) . Consistently, the CD133 + cells isolated from PLC8024, Hep3B and pHCC1 did not have superior invasion ability compared to CD133 − cells ( Figure 2B ). Further studies revealed that the CD133 + cells generated 2.5-to 10-fold more colonies than did the CD133 − cells did in most HCC cells tested ( Figure 2C ), which is consistent with the previously reported growth advantage of CD133 + cells as TICs [7] . Moreover, the CD133-overexpressing cell lines and the CD133 + tumor cells showed enhanced resistance to paclitaxel-or cisplatininduced cytotoxicity (Supplementary information, Figure  S2A and S2B), another important feature of TICs [7] . We then knocked down CD133 in the pHCC1, pHCC2 and Hep3B cells by specific shRNA ( Figure 2D ). The CD133-silenced Hep3B cells, but not pHCC1 ( Figure  2E ) or pHCC2 (Supplementary information, Figure S3A ) cells, formed fewer colonies than control cells. However, CD133 downregulation did not change the drug resistance in the Hep3B cells (Supplementary information, Figure S2C ). Collectively, these results suggest that the CD133 + cells acted as TICs and were superior in cell growth, but not in cell invasion, and that CD133 might be important for the clonogenic growth of some HCC cells.
CD44 expression was associated with vascular invasion in liver cancers
We examined the expression of other surface antigens associated with tumor metastasis, including CD44, urokinase-type plasminogen activator receptor [18] and CXC chemokine receptor 4 [19] in HCC cell lines. As shown in Supplementary information, Tables S1 and S2, it was clear that CD44 expression was associated with invasiveness.
We further examined the expression of CD44 in HCC specimens and NTs ( Figure 3A ). As shown in Figure 3B , the number of CD44 + cells in the M group was higher than that in the NM and NT groups, and CD44 staining was not different between the M and PVTT groups. In addition, some sinusoid lining cells in the normal liver and mononuclear cells in the tumor were positive for CD44. Moreover, CD44 expression was enriched at the tumor edge of metastatic HCC specimens compared with that in the tumor center ( Figure 3C and Supplementary information, Figure S1B ), which emphasized the importance of CD44 in metastasis. Taken together, these results suggest that an increased number of CD44 + tumor cells might play a role in vascular invasion.
CD44 high HCC cells were superior in vascular invasion but not in clonogenic growth
We then compared the invasive abilities of the CD44 + (CD44 high ) and CD44 − (CD44 low/− ) cells using the transwell assay. As shown in Figure 4A We also compared the number of colonies formed and the cell cycle profiles of the CD44 + (CD44 high ) and
) cells and found no difference between two groups ( Figure 4D and Supplementary information, Table S3 ). Knockdown of CD44 in the Hep3B2 and SMMC-7721 cells did not affect their growth but greatly reduced the number of invaded cells ( Figure 4E and Supplementary information, Figure S3B -S3D). Taken together, these results suggest that the CD44 high HCC cell population has a superior vascular invasion ability, but not clonogenic growth ability, and that CD44 is required for cell invasion.
CD133 + CD44 high HCC cells were responsible for tumor metastasis
Because the CD133 + and CD44 high cells were superior in clonogenic growth and invasion, respectively, CD133 + CD44 high HCC cells might be responsible for hematogenous metastasis of liver cancers. We examined tumor formation and metastasis using sorted Table S4 ), which was consistent with the results of tumor sphere formation in vitro ( Figure 5B ). In addition, our serial dilution transplantation of different subgroups of tumor cells from human HCC specimens also indicated that the CD133 + CD44 + and CD133 + CD44 − cells had a high tumorigenicity in the SCID mice (Supplementary information, Figure S4 and low/− cells ( Figure 5C b-d and f-g), although both tumors displayed analogous tumor cell morphology and density ( Figure 5C a and e) at the tumor center. In the MHCC97L-implanted mice, all the five mice injected with CD133
high cells developed tumors in the liver, and four of those developed lung metastasis. In contrast, CD133 + CD44
low/− cells did not form lung metastasis ( Figure 5D and Supplementary information, Table S4 ). Moreover, lentivirus-mediated RNAi targeting of CD133 and CD44 in the CD133 + CD44
high MH-CC97L cells failed to produce lung metastasis, although primary tumor formation in the liver was not affected (Supplementary information, Figure S5 and Table S6 ). Therefore, CD133 + CD44
high cells are a distinct population capable of inducing metastasis at very low cell numbers and in a relatively short time.
More CD133 + CD44 + tumor cells were found in metastatic than in metastasis-free HCC specimens
We next examined CD133 + CD44 + tumor cells in HCC patient specimens. The hepatic and lymphatic cells were stained by the antibodies against cytokeratin-18 (CK18) and CD45, respectively. As shown in Figure 6A , more CD45 − CD133 + CD44 + cells were detected in metastatic HCC specimens (0.24% ± 0.25%) than in non-metastatic HCC specimens (0.06% ± 0.11%). Immunostaining further confirmed that CD133 + CD44 + tumor cells, characterized as CK18 + cells between the PVTT and the primary tumor was similar (Supplementary information, Figure  S6C ). Because the total number of tumor cells in the PVTT was much smaller than that in the primary tumors, it is likely that the percentage of CD133 + CD44
+ cells in the PVTT was higher than that in the primary site. These results provided additional evidence that these cells are indeed a subgroup of cells critical for human HCC metastasis. 
Discussion
We showed here that CD133 + CD44 high cells play a key role in hematogenous metastasis of liver cancers, in which CD133 is responsible for tumor growth and CD44 is important for invasion, two important factors in tumor metastasis. Our results also suggest that CD133 + cells act as TIC-like populations because they exhibited enhanced abilities in colony formation and tumorigenicity. This may be important for tumor cells to protect against multiple insults during metastasis. However, the CD133 + tumor cells were not necessarily highly invasive [9, 15] . For example, CD133 + CXCR4 + pancreatic cancer cells, but not CD133 + CXCR4 − cells, invade aggressively [9] . We found that CD44, in addition to CD133, also had a critical role in tumor metastasis. In our work, CD133 and CD44 expression were associated with other pathological features besides PVTT formation (Supplementary information, Table S8 ), which was different from a previous report [15] . This discrepancy might be due to the difference in cohort numbers.
Recently, based on studies of HCC cell lines, CD133 + and CD44 + were proposed to be markers of TICs in liver cancers [25] . It was unknown whether the properties of CD44 + or CD44 − cells were similar to those found in HCC specimens because of a preference for CD44 expression in cell lines over HCC specimens [26] . Our results suggested that the cell lines expressing high CD44 levels were similar to the CD44 + or CD44 − cells from primary HCC in terms of cell growth and invasion, and that CD44 was a marker of an invasive, but not tumorigenic, sub-population. Although we noticed that the invasive ability of CD44 high cells varied greatly between different cell lines, this difference might be caused by their distinct genetic backgrounds as well as the involvement of other genes in the regulation of cell invasion.
The CD44 + CD90 + HCC cells were reported to be highly invasive [27] . Although both CD133 and CD90 were proposed as markers of liver progenitor cells [28, 29] , they might represent distinct populations. First, CD90 and CD133 mark for mesenchymal and hematopoietic origin, respectively [28, 30] . Second, we (data not shown) and others [22, 23] Although an important finding of the current study is that knockdown of CD133 and CD44 affected tumor growth and invasion, respectively, cDNA microarray data suggested that other molecules might also be important for the enhanced metastatic potential of CD133 + CD44 + tumor cells. We noticed that some molecules involved in the HCC metastatic process (twist, snail, slug and zeb) were not present in the differentially regulated genes [31, 32] . As these genes were overexpressed in a subgroup of HCC patients [31, 32] , increasing the patient numbers for microarray analysis might extend the list of genes expressed differently. Therefore, CD133 and CD44 could be regarded as markers of multiple pathways through which tumor metastasis is jointly promoted. As CD44 − cells might convert to CD44 + cells in some conditions (Supplementary information, Table S12) [33] , it is possible that tumor metastases in CD133 + CD44
− xenografts might be postponed, but not prevented.
In summary, the CD133 
Materials and Methods
Cell culture and materials
Human HCC cell lines, including HepG2, SMMC-7721, Hep3B, Hep3B2, Huh-7, PLC8024, MHCC97L and MHCC97H, were used in this work. Two strains of Hep3B from different sources have distinct surface antigen profiles and invasive abilities [25, 27, 34] , and one strain with high expression of CD44 was named Hep3B2. Three primary HCC cells (pHCC1, pHCC2 and pHCC3) were isolated from three HCC patient xenografts in nude mice prepared as described previously [35] . The primary HCC cells were freshly prepared and further purified using flow cytometry to exclude fibroblasts and inflammatory cells. All cell lines were maintained in Dulbecco's Modified Eagle's Medium (Gibco) with 10% fetal bovine serum (PAA Laboratories GmbH), high glucose and a penicillin-streptomycin mixture. HUVECs, purchased from ScienCell Research Laboratories, were maintained in endothelial cell medium (ScienCell Research Laboratories). All cultures were maintained at 37 °C in a humidified atmosphere of 5% CO 2 in air.
Rabbit polyclonal anti-CD133 antibody (Abcam) and mouse anti-CD44 (Neomarker) and anti-CK18 (Boster) mononclonal antibodies were used for IHC and western blot. The secondary antibody of Cy3-conjugated goat anti-mouse IgG was from Molecular Probes (Invitrogen). Mouse antibodies against CD133/2-PE (clone 293C3), CD133/1-APC (clone AC133, Miltenyi Biotec), CD44-FITC, CD44-PE-Cy5 (clone IM7, Bioscience Pharmingen, BD) and CD45-PerCP (BD) were used in flow cytometry analysis and cell sorting.
Patients and specimens
All tissue samples were obtained from consenting patients registered at the Eastern Hepatobiliary Surgery Hospital, Shanghai, between 2006 and 2009 and were approved by the Ethics Committee. Forty-eight HCC tissue samples were used for IHC. At the time of initial diagnosis, 28 patients had no major vascular invasion and were stratified into the NM group, whereas 20 patients had major vascular invasion, from which specimens of primary tumors (M) and their derived PVTTs were collected. Samples from the NM group were confirmed to be without microscopic vascular invasion. All patients underwent partial liver resections with curative intention or liver transplantation. NTs from 10 patients without liver cancer were categorized as the NT group. A total of 40 additional HCC specimens were used for flow cytometry analysis, 22 of which were associated with tumor metastasis (mHCC) and 18 of which were metastasis free (nmHCC). Five mHCC specimens were used for microarray experiments. All clinical data are summarized in Supplementary information, Table S9 .
Immunostaining
IHC and immunofluorescence were performed as previously described [36] . In the IHC studies, the IHC score was defined according to the percentages of CD133 + or CD44 + tumor cells in the samples from 15-20 random fields at 400× magnification. As shown in Supplementary information, Figure S1A , the different grades of CD133 staining intensity were defined as follows: intense, in which the immunoreaction deposit was distinctly denser than the background and tissues that did not express the antigen; equivocal, in which the immunoreaction deposit was similar to the background and/or to tissues that did not express the antigen; and none, in which no immunoreaction deposit was found. The IHC scores were arbitrarily assigned according to the percentages of CD133 + and CD44 + tumor cells: 0 = none; 1 = 0.01 to 0.9%; and 2 ≥ 1% for CD133 and 0 = none; 1 = 0.01 to 5%; and 2 ≥ 5% for CD44.
We also examined CD44 expression in the tumor bulk or tumor edge in the M group. Tumor bulk was defined as areas that were 2-3mm away from distinguishable tumor borders, and tumor edge was defined as tumor areas that were 200-300 µm wide along the tumor border under the microscope.
Colony formation and tumor sphere formation
Colonies were formed as previously described [36] . For tumor sphere formation, 1 × 10 3 tumor cells were seeded in non-adhesive 12-well plates. Two weeks after seeding, cell spheres characterized by tight, spherical, non-adherent masses > 90 µm in diameter per well were observed, and their numbers were determined. All experiments were repeated at least three times.
Flow cytometry and cell sorting
Cells were stained by different antibodies according to the manufacturer's instructions. Flow cytometry was performed in a MoFlo XDP cell sorter (Beckman Coulter), and appropriate isotype-matched antibodies were used as controls. The purity and viability of isolated cells were routinely > 90%.
Invasion and transendothelial migration
The invasion assays were performed in the transwell insert with an 8 µm pore size (Corning) coated with Matrigel (BD) according to the manufacturer's instructions. The transendothelial migration assay was performed as reported previously [37] . Briefly, 1 × 10
5
HUVECs were first seeded in the upper chamber of the transwell insert. After HUVEC growth for 24 h to a confluent layer, 5 × 10 4 stable EGFP-transfected tumor cells were placed on the HUVEC layer. After transmigration for 24 h, the migrated cells on the bottom side of the insert were visualized, and the numbers were counted under the fluorescent microscope.
For time-lapse imaging, a total of 1 × 10 5 HUVECs were first plated on customized coverslips placed at the bottoms of 35 mm Petri dishes. After 24 h of HUVEC growth to a confluent layer, 1 × 10 4 stable EGFP-transfected tumor cells were seeded on the HU-VEC layer. Unbound tumor cells were removed by a single wash after a 1-h co-culture. Tumor cells were confirmed to be GFP positive using fluorescent microscopy. The dish was then transferred to the imaging platform, which was equipped with a heat plate to maintain the temperature inside the dish at 37 °C. Mineral oil was added to the surface of the medium to avoid evaporation. The tumor cells were observed under 100× magnification using a light microscope. The image was generated by a JVC TKC1381 camera (Yokohama). One frame was taken every 6 min for 15-24 h. Images of at least five cells in each group were analyzed.
RNAi and western blot
The sequences for lentivirus-based RNAi against CD133 and CD44 are provided in Supplementary information, Table S10 . Lentivirus production was achieved as previously described [38] , and a multiplicity of infection of five was used to infect HCC cells. Total protein was extracted 72 h after infection and used for western blotting as described previously [35] . The density was quantified by scanning the bands.
Tumor xenograft models
Four-week old male BALB/c nude mice were maintained and cared according to the institutional guidelines. In brief, 1 × 10 4 sorted SMMC-7721 or MHCC97L cells were injected into the mice in the left lobes of the liver. Animals were sacrificed 3 months after implantation. npg tumor cell leakage. The lung metastasis was diagnosed as reported previously [39] and confirmed by experienced pathologists.
Microarray analysis and real-time PCR analysis
The RNA for the microarray experiments was extracted from CD133 + CD44 + and CD133 + CD44 − tumor cells, sorted from the specimens of five HCC patients with metastasis, by flow cytometry. Microarray experiments were performed in the whole human genome oligo microarray (Agilent Technologies) at the National Engineering Center for Biochip at Shanghai. Quantile normalization was used to equalize the distribution of probe intensities for each array in a set of arrays, and two-sample t-statistics were computed for each gene. Six of ten microarrays (paired arrays for three patients) were chosen for gene expression analysis based on a CD44 probe fold change ≥ 2 in the CD133 + CD44
+ groups versus the paired CD133 + CD44 − groups. The differentiated genes were selected based on the criteria of P ≤ 0.05 and a fold change of ≥ 2 of their expression values between the two groups. The array clustering was performed by Cluster 3.0. The data were deposited in the GEO database (GSE26321).
For real-time PCR, cDNA was created using the SuperScript III CellsDirect cDNA Synthesis Kit (Invitrogen) according to the manufacturer's protocol. Real-time PCR was performed on the LightCycler 480 (Roche) using the LightCycler 480 SYBR Green I Master Kit according to the manufacturer's protocol. Primer sequences are provided in Supplementary information, Table S11 . For each target gene, the fold change in expression levels between normal and tumor specimens was evaluated using the 2 -ΔΔCt method. Raw data were normalized using values from the 18SrRNA reference gene. For each cell line or patient, the normalized values of each biological triplicate were averaged before the calculation of the -ΔΔCt using the CD133 + CD44 − or the CD133 + CD44
low/− group as a calibrator.
Statistical analysis
Results for continuous variables were expressed as mean ± SD. The Kruskal-Wallis χ 2 -test was used to determine the significance of association between groups or proportions. Student's t-test was used to compare the means of results where appropriate. A value of P ≤ 0.05 was considered statistically significant. All analyses were performed using SPSS 11.5 software (SPSS).
